Gastrointestinal Cancer | Specialty

Dr. Jones on Selecting Between Frontline Regimens in Pancreatic Cancer

March 5th 2021

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

Frontline Nivolumab Plus Chemo Shows Practice-Changing Potential in GI Cancers

March 5th 2021

Yelena Y. Janjigian, MD, discussed the promise of nivolumab plus chemotherapy in patients with PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma, as well as important biomarkers that should be used to guide sequencing decisions.

Dr. Levy on Future Research Directions for Lenvatinib in HCC

March 4th 2021

Anna T. Levy, DO, discuses future research directions for lenvatinib in patients with hepatocellular carcinoma.

Dr. Philip on the Efficacy of TAS-102 in mCRC

March 4th 2021

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.

Dr. Singal on the Utility of Frontline Lenvatinib and Sorafenib in Advanced HCC

March 2nd 2021

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

Gastric/GEJ Cancers Gain Traction With HER2-Targeted Therapy With More to Come

March 2nd 2021

Daniel H. Ahn, DO, and Manish A. Shah, MD, discuss the emergence of HER2 as a validated target in GI malignancies, the approval of trastuzumab deruxtecan in gastric/GEJ cancer, and other emerging agents that are poised to propel HER2-targeted therapy in these diseases.

FDA Approval Sought for Ivosidenib in Previously Treated IDH1-Mutant Cholangiocarcinoma

March 1st 2021

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Personalized Radioembolization Improves OS Vs Standard Dosing in Advanced HCC

March 1st 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

Bekaii-Saab Shares Suggested Sequencing Algorithm for Advanced HCC

February 26th 2021

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

February 25th 2021

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.